AbbVie (ABBV) Non-Current Debt (2012 - 2026)

AbbVie (ABBV) has reported Non-Current Debt for 15 consecutive years, with $62.5 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Debt fell 0.76% year-over-year to $62.5 billion in Q2 2026; TTM through Jun 2026 was $62.5 billion, a 0.76% decrease from a year earlier, with the FY2025 full-year figure at $58.9 billion, down 2.32% from the prior year.
• Non-Current Debt was $62.5 billion for Q2 2026 at AbbVie, down from $64.5 billion in the prior quarter.
• Over five years, Non-Current Debt peaked at $64.5 billion in Q1 2026 and troughed at $52.2 billion in Q4 2023.
• A 5-year average of $60.2 billion and a median of $60.4 billion in 2022 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt decreased 18.43% in 2022 and advanced 15.61% in 2024, its largest moves.
• Over 5 years, Non-Current Debt stood at $59.1 billion in 2022, then dropped by 11.74% to $52.2 billion in 2023, then rose by 15.61% to $60.3 billion in 2024, then decreased by 2.32% to $58.9 billion in 2025, then climbed by 6.01% to $62.5 billion in 2026.
• The last three Non-Current Debt figures came in at $62.5 billion (Q2 2026), $64.5 billion (Q1 2026), and $58.9 billion (Q4 2025), per Business Quant data.